Navigation Links
Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
Date:5/5/2009

ements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of KRYSTEXXA and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of KRYSTEXXA; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated wit
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
2. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
3. Cost-Cutting Plus Value-Add Defines Qualitys Role in a Recession
4. PhRMA, Families USA Jointly Promote Measures to Ensure Quality, Affordable Healthcare Coverage
5. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
6. EPA Awards Lovelace Respiratory Research Institute $500,000 for Air Quality Research
7. World's First Website for Patients to Share Diagnostic-Quality Medical Images
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
10. Managing Risk Through Quality: Ansell Healthcares Innovative Gammex(R) Glove Range on Display at Arab Health 2009
11. New Initiative Focuses on Water Quality Improvement in the Mississippi River Basin and Gulf of Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... Covance Inc. (NYSE:,CVD) today announced that it will ... Tuesday, May 13, 2008 at 10:30 am ET. Investors ... http://www.covance.com . In order to,register and download any necessary ... headquarters in Princeton, New Jersey, is one of the,world,s ...
... SAN CLEMENTE, Calif., May 12 USGI Medical, ... that the company has,licensed its incisionless surgery technology ... robotics applications. Financial terms of the deal,were not ... and clinical development,including their intellectual property," said Gary ...
... Bulletin Board: NURX pre split, NUXP post split) today ... split became,effective. The Company has been informed by the ... connection with the reverse stock,split, its trading symbol has ... split will reduce the number of issued and,outstanding shares ...
Cached Biology Technology:USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 2USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 3NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect 2
(Date:7/25/2014)... (NRG1) is a pleiotropic factor characterized by the ... of exons that confer to the protein deeply ... both the myelination occurring during development and the ... nerve: axon degeneration, axon regrowth, remyelination and target ... have discovered that the soluble NRG1 upregulation observed ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... there is a serious influenza outbreak will do little to ... findings of a study conducted at the UK Health Protection ... Sometimes a new type of influeza virus appears that causes ... case for flu. This happened, for example, in 1918, when ...
... defined the collective genome of the human gut, or colon. ... make up a motley "microbiome" that allows humans to digest ... fiber. , In a study published in the June ... for Genomic Research (TIGR) and their colleagues describe and analyze ...
... spend $21 billion for HIV/AIDS research, treatment, prevention, and ... study published in the July 1 issue of The ... it is--and more so than previously thought. , The ... , MD, MSc and colleagues at Massachusetts General Hospital ...
Cached Biology News:Air travel and pandemic flu 2Gut reaction: Researchers define the colon's genome 2Gut reaction: Researchers define the colon's genome 3New study calculates millions of years saved in lives of AIDS patients 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Reactivity: Human...
... Transformation Kit is designed for rapid ... Advantages over commonly used transformation procedures ... methods include:- Cells can be made competent ... cell preparation and transformation solutions are ...
...
Biology Products: